~	eg.			No.					
2	A	a		- 1	1	1	n		
1	6	č.,	•			1	υ	٠	

MANIPAL UNIVERSITY

SECOND YEAR PHARM D (POST BACCALAUREATE)/FIFTH YEAR PHARM D. DEGREE EXAMINATION – MAY 2013

SUBJECT: PD 5.1: CLINICAL RESEARCH

Friday, May 24, 2013

Time: 10:00 - 13:00 Hrs.

Max. Marks: 70

- ∠ Long Essay questions:
- 1. Explain the scope and purpose of ICH-GCP guidelines and outline its principles.

(4+6 = 10 marks)

2. Explain composition of ethics committee as per ICMR ethical guideline/schedule-Y. Comment on decision making process at ethics committee.

(6+4 = 10 marks)

3. What is NDA? Explain the contents and process of NDA.

(2+8 = 10 marks)

4. Short Essay questions:

- 4A. Explain the steps involved in preclinical drug development with illustrations.
- 4B. Discuss the details of 'effect in humans' and 'non clinical studies' incorporated in Investigator's Brochure.
- 4C. Explain the informed consent process and comment on compensation for participating in a trial.
- 4D. Describe the procedure for carcinogenicity test.
- 4E. Describe the 'background information' and 'trial design' of a clinical trial protocol.
- 4F. Discuss premature termination/suspension of a clinical trial according to ICH-GCP.

 $(5 \times 6 = 30 \text{ marks})$

5. Short Answer questions:

- 5A. Define sponsor and investigator as per ICH-GCP guidelines.
- 5B. Outline the procedure acute toxicity studies.
- 5C. Enlist the methods of post marketing surveillance.
- 5D. Outline the responsibilities of auditors in clinical trials.
- 5E. List the records to be maintained with IRB/IEC

 $(2 \times 5 = 10 \text{ marks})$



	Reg. No.					
1.03	1108. 1101	 	 			

MANIPAL UNIVERSITY

SECOND YEAR PHARM D (POST BACCALAUREATE)/FIFTH YEAR PHARM D. DEGREE EXAMINATION – MAY 2013

SUBJECT: PD 5.2: PHARMACOEPIDEMIOLOGY AND PHARMACOECONOMICS

Monday, May 27, 2013

Time: 10:00 - 13:00 Hrs.

Max. Marks: 70

Long Essay questions:

- 1A. Explain the major predictor of poor adherence to medication.
- 1B. Explain time-risk relationship in Pharmacoepidemiological studies with suitable examples.

(5+5 = 10 marks)

- 2A. Explain the contents of an Ideal Automated Data System.
- 2B. Explain Medical Record Automated Database system with its application.

(5+5 = 10 marks)

 Define Pharmacoeconomics and explain various steps employed for conducting Pharmacoeconomics evaluations.

(10 marks)

4. Short Essay questions:

- 4A. Define Pharmacoepidemiology and explain Scope of Pharmacoepidemiology in drug regulation.
- 4B. Define and explain information flow in Record Linkage System (RLS).
- 4C. Explain various clinical and methodological problems of drug-induced birth defect studies.
- 4D. Explain cost- utility analysis with suitable examples.
- 4E. Explain various function of WHO Global Drug Surveillance.
- 4F. Explain cross sectional studies with suitable examples.

 $(5 \times 6 = 30 \text{ marks})$

5. Short Answer questions:

- 5A. Explain Defined Daily Doses (DDD) with suitable examples.
- 5B. Write a short note on Health Related Quality of Life.
- 5C. Write a short note on Case Reports.
- 5D. Write advantages and disadvantages of prescription event monitoring.
- 5E. Define 'Signal' and explain its role in adverse drug reaction monitoring.

 $(2 \times 5 = 10 \text{ marks})$

MANIPAL UNIVERSITY

Reg. No.

SECOND YEAR PHARM D (POST BACCALAUREATE)/FIFTH YEAR PHARM D. DEGREE EXAMINATION – MAY 2013

SUBJECT: PD 5.3: CLINICAL PHARMACOKINETICS AND PHARMACOTHERAPEUTICS DRUG MONITORING

Wednesday, May 29, 2013

Time: 10:00 - 13:00 Hrs.

1. Explain the genetic polymorphism of G6PD and N-Acetyltransferase and its effect on drug metabolism.

(10 marks)

(10 marks)

Max. Marks: 70

- 2. Explain methods for analysis of population pharmacokinetic data.
- 3. Explain the following types of drug-drug interactions with examples:
- 3A. Absorption interactions
- 3B. Distribution interactions
- 3C. Elimination interactions

(10 marks)

4. Short Essay questions:

- 4A. Describe the process of conversion from Intravenous dosage to oral dosing.
- 4B. Explain the mechanisms of enzyme inhibition in drug metabolism.
- 4C. Describe general considerations for dosage adjustment in children.
- 4D. Mention the objectives and procedures for carrying out TDM.
- 4E. Explain Bayesian theory with an example.
- 4F. Explain the factors affecting dialyzability of a drug.

 $(5 \times 6 = 30 \text{ marks})$

5. Short questions:

- 5A. Enumerate four enzyme inhibitors.
- 5B. Mention the formula to calculate dosing body weight in obese patients.
- 5C. Define direct link model for pharmacokinetic and pharmacodynamic correlation.
- 5D. Mention the therapeutic range of any two anti-epileptic drugs.
- 5E. Mention the alleles for the gene of N-Acetyltransferase.

 $(2 \times 5 = 10 \text{ marks})$